These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Host-guest supramolecular hydrogel based on nanoparticles: co-delivery of DOX and siBcl-2 for synergistic cancer therapy.
    Author: Peng D, Gao H, Huang P, Shi X, Zhou J, Zhang J, Dong A, Tang H, Wang W, Deng L.
    Journal: J Biomater Sci Polym Ed; 2019 Jul; 30(10):877-893. PubMed ID: 31025910.
    Abstract:
    Synergistic therapy that combines drug/siRNA for the solid tumor treatment is becoming more and more popular to reduce the side effects and enhance the antitumor efficiency. Given that, a novel injectable supramolecular hydrogel mPECT(D)/GDDC-4(R)/α-CDgel (mPECT(D) represents DOX-loaded methoxy poly(ethylene glycol)-b-poly(ε-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-un-decanone) (mPECT) nanoparticles, GDDC-4(R) represents siBcl-2-loaded PG-P(DPAx-co-DMAEMAy)-PCB (GDDC-4) complexes nanoparticles (NPs)) was prepared via the incorporation of GDDC-4/siRNA complexes NPs into the DOX-loaded mPECT NPs/α-CDgel formed by the host-guest interaction between mPEG and α-CD. In vitro degradation and release experiments revealed that siBcl-2 was released from mPECT(D)/GDDC-4(R)/α-CDgel in the form of GDDC-4/siBcl-2 complexes NPs with bioactivity, and the release behavior of DOX also demonstrated sustained-release property. Compared to the single treatment groups, the enhanced cytotoxicity to SKOV3 and HeLa cells of mPECT(D)/GDDC-4(R)/α-CDgel was observed in vitro. Moreover, in vivo experiments also indicated the significant antitumor effect of mPECT(D)/GDDC-4(R)/α-CDgel, suggesting the remarkable synergistic therapy of DOX and siBcl-2. Therefore, this work would provide a prospective platform to co-delivery of drugs and siRNA to improve the treatment effect of solid tumor.
    [Abstract] [Full Text] [Related] [New Search]